Journal September 25, 2026 7 min read

Adipotide vs BPC-157 capsules: what the research compares

A comparison of the published research on Adipotide and BPC-157 capsules, covering what each compound is, what studies measured, where evidence is stronger, and what remains unknown.

peptides-pro Editorial

Adipotide (also known as FTPP, a synthetic peptidomimetic) is a chimeric peptide that targets the vascular endothelium of white adipose tissue. BPC-157 (body protection compound 157, pentadecapeptide BPC 157) is a synthetic pentadecapeptide derived from a gastric protein fragment [3]. The two compounds differ in class, primary research focus, and the maturity of their evidence bases. Adipotide is not mentioned in the supplied evidence block; therefore, this article cannot report on its sequence, formula, molecular weight, or any published studies. BPC-157 is described in the evidence as a pentadecapeptide with reported cytoprotective and regenerative properties across multiple organ systems [3].

The research on BPC-157 centres on pathways involving angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide modulation, as well as inflammatory cytokine activity and pain modulation through peripheral and dopaminergic mechanisms [4]. No comparable pathway information is available for Adipotide in the provided evidence.

Research Studies

BPC-157 and tendon healing in rotator cuff repair

A randomized, double-blind, placebo-controlled pilot trial is investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR) [1]. Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. Participants will self-administer subcutaneous injections daily for 90 days following surgery, with all other aspects of care following the standard postoperative protocol [1]. This study is ongoing; no results are reported in the evidence.

BPC-157 and acute hamstring muscle strain repair

A randomized, double-blind, placebo-controlled Phase 2 study is evaluating whether pentadecapeptide BPC 157 can speed structural healing and functional recovery after an acute grade II hamstring muscle strain [7]. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14 [7]. This trial is ongoing; no outcomes are available.

BPC-157 and acetylcholinesterase inhibition

In a study using a modified Ellman assay and Lineweaver-Burk analysis, the inhibitory potential of BPC-157 and two newly designed hybrid analogs (CIARA-1 and CIARA-2) was investigated for the first time [2]. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites [2]. All tested compounds showed activity, but the evidence does not specify the potency or selectivity of BPC-157 relative to the analogs.

BPC-157 and tissue repair mechanisms in preclinical models

Experimental evidence indicates that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue [4]. Studies also report reduced inflammatory cytokine activity, improved microvascular integrity, and beneficial effects on pain modulation through peripheral and dopaminergic mechanisms [4]. These findings are from preclinical models; the review notes that although animal data indicate favorable safety and pharmacokinetic profiles, human data are limited [4].

BPC-157 and biopharmaceutical development challenges

A critical review of BPC-157 from a biopharmaceutical and drug development perspective notes that despite over three decades of preclinical research demonstrating consistent biological activity, its pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial [3]. The review examines physicochemical and pharmacokinetic properties, formulation challenges across routes of administration, and translational barriers [3].

BPC-157 and peptide supplements in sports medicine

A scoping review summarised existing peer-reviewed data on six emerging peptides, including BPC-157, for musculoskeletal recovery and enhancement in animal and human models [5]. The review notes that the peptide supplement market has experienced rapid growth due to marketing claims of enhanced performance and accelerated recovery, and that these peptides are often perceived as low risk despite the absence of efficacy or safety data for many emerging peptides [5].

BPC-157 and therapeutic peptides in gerontology

A comprehensive narrative review of therapeutic peptides with applications in healthy aging and age-related conditions included BPC-157 among the peptides examined [6]. The review targeted hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline, and searched PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026 [6]. The evidence does not provide specific findings for BPC-157 in this context.

BPC-157 and peptide gummies in physically active adults

A clinical trial is evaluating the effects of Parlay Recover peptide gummies (containing Body Protection Compound BPC-157) on markers of inflammation, physical performance, and recovery in physically active adults [8]. Over an 8-week period, 40 participants will consume two gummies daily and complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8, as well as undergo blood testing at Baseline and Week 8. The primary objective is to examine changes in inflammatory biomarkers (hs-CRP and IL-6) as measured by blood testing; secondary objectives include evaluating participants' self-reported perceptions of the product's effects on physical performance and recovery, including aching, stiffness, and other symptoms [8]. This study is ongoing; no results are reported.

BPC-157 and Achilles tendon healing in rats

A study evaluated the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model [9]. The study used thirty-two male Sprague-Dawley rats. The evidence does not provide the results of this study.

BPC-157 and chitosan hydrogel fabrication

A study fabricated and characterized a CH/BPC composite hydrogel for physicochemical properties [10]. The formulation exhibited a porous structure, analyzed through scanning electron microscopy (SEM) and transmission electron microscopy (TEM). The evidence does not provide further details on the results or applications.

BPC-157 and expression in Bacillus licheniformis

A study reported stable expression of γ-Glutamyltranspeptidase (GGT)-BPC157 and mScarlet-BPC157 in Bacillus licheniformis strain 2709 by chromosomal integration [11]. Fermentation conditions were optimized using single-factor and orthogonal experiments to maximize yield, with optimal conditions including 2% inoculum, 40 g/L soybean peptone, and 80 (units not specified) [11]. The evidence does not provide the yield or activity of the expressed peptides.

BPC-157 and regenerative medicine for chronic pain

A narrative review summarised current evidence on regenerative peptides relevant to chronic pain management, including collagen peptides, BPC-157, thymosin beta-4 (TB-4), thymosin beta-500 (TB-500), glycyl-L-histidyl-L-lysine copper (GHK-Cu), and growth hormone-related peptides [12]. The evidence does not provide specific findings for BPC-157 in this context.

Comparison of evidence

Feature	Adipotide	BPC-157
Class	Not specified in evidence	Synthetic pentadecapeptide [3]
Primary research focus	Not specified in evidence	Tissue repair, inflammation, pain modulation [4]
Human clinical trials	None reported in evidence	Ongoing pilot and Phase 2 trials [1][7][8]
Preclinical evidence	None reported in evidence	Extensive, over three decades [3]
Approved formulation	Not specified in evidence	None [3]
Validated dosing regimen	Not specified in evidence	None [3]
Completed Phase II trial	Not specified in evidence	None [3]

What is not known

For Adipotide, the provided evidence contains no information on its sequence, formula, molecular weight, mechanism, or any published studies. Therefore, no comparison of research findings can be made. For BPC-157, despite extensive preclinical research, there is no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial [3]. The scoping review notes the absence of efficacy or safety data for many emerging peptides, including BPC-157, in human models [5]. The ongoing clinical trials have not reported results [1][7][8]. The evidence does not establish a winner; it shows that BPC-157 has a larger body of preclinical and early-phase clinical research, while Adipotide is absent from the supplied evidence.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.